Premaitha Share Discussion Threads

[gnnmartin] 08/9/2016 12:32

Thanks brains & sh, the RNS was pushing me towards selling. The evidence that Evans' decision is probably personal has made me decide to hold.

[sh1984] 08/9/2016 12:03

Also left the board of Scancell a few months ago, just seems like a personal decision more than anything............ won't influence imminent results.

[brainspark1] 08/9/2016 10:13

He also stepped down from optibiotix on the 26th Aug
from the opti RNS of the same date

"David Evans is stepping down from the Board? as of today reflecting a personal desire to reduce his overall number of commitments. Adam Reynolds will assume the role of Chairman in the interim. The Board would like to take this opportunity to thank David Evans for his substantial effort, contribution and support since the conception of the Company through to its admission to AIM in July 2014."

[hjb1] 08/9/2016 09:34

it would be good to get some explanation why.Mind you they never tell you the real reasons anyway.

[thinkbig?] 08/9/2016 09:20

Looks like problems at Board level now. !! Not happy about this !!

[twix386] 08/9/2016 09:20

RNS

Directorate Change

Manchester, UK - 8 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system, announces that David Evans, Non-executive Chairman, has stepped down from the Board with immediate effect. Adam Reynolds, Non-executive Director, will become Non-executive Chairman on an interim basis until such time as a new permanent chairman is appointed.

Adam Reynolds, Non-executive Chairman, commented:

"On behalf of the Board I would like to thank David Evans for his enormous contribution to Premaitha. David has provided valuable counsel since the Company's admission to AIM in 2014 and leading up to our successful commercialisation of the IONA(R) test, which is now being used in multiple countries around the world as a safe and fast non-invasive prenatal screening system."

[sh1984] 08/9/2016 07:42

What about Genoma, GE Next, the India contract? I think we will all be pleasantly surprised when the results are in

[thinkbig?] 08/9/2016 07:05

I would be worried as no new contracts. The rise has been all on speculation !!! The contracts they all ready have. Just hope they have sold plenty Plus NHS still don't know if they have contract.

[sh1984] 07/9/2016 12:12

Does anyone know when the interim results are due? should be any moment this month I presume?

Hoping for some news before the AGM next month, it's been a while since last RNS - surely can't be long for results now?

[ewads] 04/9/2016 14:42

Not Premaitha but IONA must give similar results, all things being equal with the alleged patent infringement?

[timojelly] 04/9/2016 10:53

Premaithas obvious next step

[timojelly] 04/9/2016 10:52

WT flipping ek! Interested to find out which test they used.

[dire cons] 02/9/2016 16:26

It was only gossip sh, interestingly it was never denied by either party though.
Maybe they thought it too ridiculous to bother commenting on?

[sh1984] 02/9/2016 14:50

What's happened with the Fishers bid? seems to have gone quiet recently

[timbo003] 29/8/2016 21:12

Worth a read:

[brainspark1] 23/8/2016 07:45

Not many AIM companies delivering triple digit growth.

[captain_kurt] 23/8/2016 07:24

Excellent news.

[gooosed] 23/8/2016 07:23

Thanks twix - encouraging. A good result re NHS and we should see this move.

[twix386] 23/8/2016 07:09

Genoma sales increased by 171 % compared to the same period last year and 58% compared to the HY 2 2015. The main product, Tranquility has confirmed its appeal to patients, doctors, laboratories and different distribution partners. Serenity along with the other Genoma tests continues its development. Genoma shows a
consistent and increasing strong sales intake. The company expects an important development of the global market as many national public health systems are now covering the costs of genetic NGS testing and more specifically NIPT.

[twix386] 23/8/2016 07:08

Esperite N.V. (ESP) publishes revenue increase of 6% compared to HY1 2015 and 8% to HY2 2015; Significant EBITDA improvement from minus EUR 2.8 million in HY2 2015 to minus EUR 1.5 million HY 2016

[timbo003] 21/8/2016 12:21

Thanks Brainspark

Here's he link: